HIV/AIDS-associated Fatigue
Conditions
Keywords
Fatigue, HIV/AIDS, American ginseng, Panax quinquefolius, Fatigue Severity Scale, CD4 count, plasma HIV RNA, cytokines, IL-6, sTNFR1, sTNFR2
Brief summary
The purpose of this study is to determine whether American ginseng is effective in the treatment of HIV-associated fatigue.
Detailed description
STUDY DESIGN Chronic fatigue is a major problem for HIV-infected patients and contributes to decreased quality of life and physical functioning, higher levels of psychological distress, and antiretroviral non-adherence. The etiology of fatigue in HIV-infected patients is unknown, but changes in systemic inflammation may play a contributing role. The mechanism of action of ginseng in the treatment of fatigue is also not clear, but in its role as a purported adaptogen, it may decrease fatigue by altering systemic inflammation. Ginseng is one of the most popular botanical products in the US and is marketed to improve fatigue and vitality. Our preliminary data suggested that American ginseng at 1000-2000 mg/day may decrease fatigue in cancer patients. HIV-infected patients frequently use ginseng, in part because they perceive these therapies to be safer than more conventional therapies. We hypothesized that a standardized American ginseng formulation will improved HIV-related fatigue. To test this hypothesis we propose a 6-week double-blind, placebo-controlled trial, parallel study of four weeks of treatment involving two doses of American ginseng or placebo (1000mg/day or 3000 mg/day) in 120 HIV-infected patients with clinically significant fatigue, as defined by their scores on the Fatigue Severity Scale. Patients will be treated with American ginseng or placebo every morning for a total of two doses of 1000 mg/day or 3000 mg/day. A smaller cohort of 12 out of 120 subjects will be enrolled initially to monitor closely for confirmed virologic failure, If confirmed virologic failure is not observed, enrollment will continue to the proposed 120 subjects. Virologic failure is defined as two consecutive plasma viral loads \>200 cells according to the 2012 Department of Health Humans Services Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents The proposed doses of American ginseng are the same as those used in our previous trials. American ginseng 1000 mg/day showed efficacy in ameliorating fatigue in cancer patients. The highest dose of American ginseng (3000 mg/day) selected for this study was derived from our previous American ginseng trial. Change on scores of the Fatigue Severity Scale (FSS) between American ginseng and placebo groups at baseline, and treatment weeks 2, 4, and 6 (the last safety visit two weeks after completing the 4-week treatment period with American ginseng or placebo) will be calculated. The primary comparison of interest will involve the primary endpoint of the average change in the FSS scale score from baseline to the end of treatment. Other instruments to supplement the FSS and further assess fatigue will be a modified version of the Brief Fatigue Inventory (BFI), The Epworth Sleepiness Scale (ESS), the Patient Health Questionnaire (PHQ-9), Insomnia Severity Index (ISI), the Medical Outcomes Study HIV Health Survey (MOS-HIV), the Clinical Global Impressions (CGI) of Change Scale, and Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue. To further elucidate the mechanism of HIV-related fatigue, we will evaluate the effects of American ginseng and placebo on markers of systemic inflammation such as IL-6 and soluble receptors of tumor necrosis factor (TNF) α 1 and 2 (sTNFR1 and sTNFR2), at baseline and weeks 2, 4, and 6. cluster of differentiation 4 (CD4) cell counts, plasma HIV RNA levels, and adverse events (AEs) will also be assessed for safety purposes. DURATION: The total duration of this study is 6 weeks. Participants will receive American ginseng or placebo during the first 4 weeks of the study. On week 6 participants will complete their final post treatment safety study visit. POPULATION AND SAMPLE SIZE: 120 HIV-infected subjects (40 in the American ginseng 1000 mg/day arm, 40 in the American ginseng 3000 mg/day arm, 20 in the placebo 1000 mg/day arm, and 20 in the placebo 3000 mg/day arm). REGIMEN: This is a randomized, placebo-controlled, longitudinal, parallel study with two doses of American ginseng. As shown in the study schematic figure, two doses of American ginseng or placebo (1000 or 3000 mg/day) will be given to 120 HIV-infected patients (40 in the American ginseng 1000 mg/day arm, 40 in the American ginseng 3000 mg/day arm, 20 in the placebo 1000 mg/day arm, and 20 in the placebo 3000 mg/day arm) with clinically significant fatigue. Participants will receive American ginseng or placebo for a total of 4 weeks and will be followed for a total of 6 weeks (week 6 is the last safety visit 2 weeks after completing the 4-week treatment period with American ginseng or placebo). American ginseng will be continued for Grades 1 and 2 toxicities at the discretion of the investigator. Treatment will be discontinued for subjects experiencing any grade ≥3 study drug toxicity. Evaluations for the early termination visit will be completed for these subjects. Participants who discontinue treatment secondary to toxicity will be followed until resolution, return to baseline values, or an adequate explanation can be given for their condition. Subjects requiring dose modifications/reductions/interruptions of American ginseng/placebo to manage toxicities will be followed off study drugs. The total number of patients accrued hence will be 120 patients (40 in the American ginseng 1000 mg/day arm, 40 in the American ginseng 3000 mg/day arm, 20 in the placebo 1000 mg/day arm, and 20 in the placebo American ginseng 3000 mg/day arm). STUDY DURATION The total duration of this study is six weeks. Participants will receive American ginseng or placebo during the first 4 weeks of the study. On week 6 participants will complete their final post treatment safety study visit. STUDY AGENT/INTERVENTION DESCRIPTION Two doses of American ginseng or placebo (1000 mg/day or 3000 mg/day) every morning by mouth for a 4-week period. PRIMARY AND SECONDARY OBJECTIVES The overall objective of this study is to determine the effect of American ginseng on fatigue in HIV-infected subjects. HIV-infected subjects with fatigue will be randomized to receive two doses (1000 mg/day or 3000 mg/day) of standardized American ginseng or placebo, and their levels of fatigue and quality of life will be assessed. We will also quantify proinflammatory cytokines in the placebo and American ginseng-treated groups to further elucidate the mechanism of HIV-related fatigue, and the effects of American ginseng on these markers. ENDPOINTS Primary Endpoint: Change in FSS total score from baseline to end of four weeks of treatment. Secondary Endpoints: Change from baseline and values observed at 2, 4, and 6 weeks post-baseline for the following measures: BFI-global assessment score ESS score PHQ-9 total score ISI score MOS-HIV scale total score, Gene Importance Calculator (GIC) score PROMIS fatigue scale score Serum cytokines (IL-6, sTNFR1, sTNFR2) CD4 cell counts, proportion with detectable plasma HIV RNA, AEs will be measured using the Division of AIDS Table for Grading the Severity of Adults Adverse events.
Interventions
DRUGAmerican ginseng
American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
DIETARY_SUPPLEMENTPlacebo for American ginseng
Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks. Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day
Sponsors
National Center for Complementary and Integrative Health (NCCIH)
Johns Hopkins University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. HIV-infected men and women, ≥18 years of age 2. HIV-1 infection documented by a rapid HIV test or any licensed ELISA test kit and confirmed by a repeat ELISA, Western blot at any time prior to study entry; or documentation of ongoing HIV/AIDS care, or treatment for AIDS, or previous positive HIV serology at any time prior to study entry 3. On stable antiretroviral therapy for at least three months 4. Undetectable plasma HIV RNA using conventional assays with lower limits of quantification (20-75 copies/ml) obtained within 30 days prior to entry 5. The following laboratory values obtained within 30 prior to study entry: Absolute neutrophil count (ANC) ≥750/mm3 Hematocrit ≥30 Platelet count ≥40,000/mm3 Calculated creatinine clearance (CrCl) ≥50 mL/min, as estimated by the Cockcroft-Gault equation\* aspartate amino transferase (AST) serum glutamic oxalacetic transaminase (SGOT), amino alanine transferase (ALT) serum glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase \<3 x upper limit of normal (ULN) total bilirubin ≤2.5 x ULN NOTE: If the potential subject is taking an atazanavir-containing regimen at the time of screening, total bilirubin ≤5 x ULN is acceptable \* Calculation for the Cockcroft-Gault equation is available at https://www.fstrf.org/common/utilities/calculators/ccc.html 6. Clinically significant fatigue (≥4.5 on the FSS) 7. PHQ-9 Questionnaire score \<10 8. ISI Questionnaire \<14 9. On stable psychiatric medications for at least 8 weeks prior to enrollment. 10. Ability and willingness of subject to provide a signed informed consent and comply with all study requirements 11. Laboratory values and physical examination as judged by the principal investigator to be safe to participate 12. Females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, specifically hysterectomy, or bilateral oophorectomy or tubal ligation) will need a negative serum or urine pregnancy test within 30 days prior to entry. NOTE: Acceptable documentation of hysterectomy and bilateral oophorectomy, tubal ligation, tubal micro-inserts, and menopause is self-reported history. 13. All potential subjects must agree not to participate in the conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the subject/ partner must reliable methods of contraception (condoms, with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an intrauterine contraceptive device (IUD); or hormone-based contraceptive) while receiving study treatment. Subjects will be encourage to use a barrier method of contraception (e.g. condoms) along with hormonal contraceptives during administration of American ginseng.
Exclusion criteria
1. Untreated hypothyroidism (TSH \>4.5 milli-international units per liter (mIU/L)) 2. Untreated or undertreated hypogonadism (calculated free testosterone below The lower limit of normal) 3. Untreated or under-treated major depressive disorder 4. No change in testosterone therapy within 6 weeks prior to screening 5. As determined by the investigator, history of chronic or acute medical condition that in the opinion of the investigator would jeopardize safety of subjects participating in this study 6. Hospitalization or therapy for serious illness within 30 days prior to study entry as judged by the investigator 7. Known allergy/sensitivity or any hypersensitivity to components of American ginseng 8. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence or subject compliance with study requirements (stable methadone treatment allowed) 9. Current use or requirement for any medications prohibited with study treatment including warfarin. (Lists of prohibited medications are contained in the Prohibited Medications Section of the protocol) 10. Pregnancy or breastfeeding 11. Use of any immunomodulator (e.g., interferons, interleukins, systemic corticosteroids, cyclosporine), vaccine, or investigational therapy within 30 days prior to study entry 12. Treatment with investigational study drugs/vaccines 13. Co-enrolment in observational trials is allowed if the blood volume requirement does not exceed the Red Cross limits specified for this clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Fatigue Severity Score (FSS) | From baseline to week 4 (28 days of study drugs) | Change in FSS score from baseline to Week 4. The change in fatigue as measured by the FSS (Week 4 minus Baseline) using the Wilcoxon test. The FSS is a scale score ranging from 1 to 63 with higher scores indicative of more fatigue. A negative number indicates a decline in the FSS scale. Participants with FSS data at both times points were assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Epworth Sleepiness Scale | From baseline to week 4 (28 days of study drugs) | Questionnaire: Change in Epworth Sleepiness Scale (ESS) score from baseline to week 4. The ESS is scale ranges from 0 to 24; higher scores mean worse sleep disorder while a negative score indicates less sleep disorder. The ESS was used to supplement the data obtained from the FSS. |
| Change in Patient Health Questionnaire 9 | From baseline to week 4 (28 days of study drugs) | Questionnaire: Change in Patient Health Questionnaire 9 (PHQ9) score from baseline to week 4. The scale for the PHQ9 score ranges from 0 to 27; higher scores mean worse depression; negative scores indicate less depression. We compared PHQ 9 scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. The PHQ9 was used to supplement the data obtained from the FSS. |
| Change in Insomnia Severity Index | From baseline to week 4 (28 days of study drugs) | Questionnaire: Change in Insomnia Severity Index (ISI) score from baseline to week 4. The ISI scale ranges from 0 to 28; higher scores mean worse insomnia while negative scores indicate less insomnia. The ISI was used to supplement the data obtained from the FSS. |
| Change in Medical Outcomes Study HIV Health Survey | From baseline to week 4 (28 days of study drugs) | Questionnaire: Change in Medical Outcomes Study (MOS) HIV Health Survey score from baseline to week 4. We evaluated the MOS Energy Fatigue scores; the MOS scale ranges from 0-100; higher scores mean more energy. The MOS was used to supplement the data obtained from the FSS. |
| Changes in Clinical Global Impressions | From baseline to week 4 (28 days of study drugs) | Questionnaire: Change in Clinical Global Impressions (CGI) scores from baseline to week 4. CGI is an instrument for making global assessments of worsening or improvement during interventional trials. The subject rates the change in the overall status since beginning the intervention (ranging from: very much improved, much improved, minimally improved, no change, and minimally worse). We assessed the number of participants who rated very much improved. |
| Change in the Brief Fatigue Inventory | Change in BFI scores from baseline to week 4 (28 days of study drugs) | Questionnaire: Change in the Brief Fatigue Inventory (BFI) from baseline to week 4. We compared BFI scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. We used the BFI Question that assess Worst Fatigue score: 0 to 90 scale. Higher scores means more fatigue; negative values mean less fatigue.The BFI was used to supplement the data obtained from the FSS. |
| Change in CD4 Cell Count | From baseline to week 5 (28 days of study drugs) | Laboratory: Change in absolute cluster of differentiation 4 (CD4) cell count from baseline to week 5. Negative values mean decline in CD4 cell count. |
| Change in Plasma HIV RNA | From baseline to week 4 (28 days of study drugs) | Laboratory: Change in plasma HIV RNA from baseline to week 4. A negative value means a drop in plasma HIV RNA. |
| Change in PROMIS Fatigue | From baseline to week 4 (28 days of study drugs). | Questionnaire: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue score from baseline to week 4. Change in PROMIS fatigue score from baseline to Week 4. The change in fatigue as measured by the PROMIS fatigue (Week 4 minus Baseline) using the Wilcoxon test. The PROMIS fatigue is a scale with normalized mean of 50 and standard deviation (SD) of 10. Higher mean values mean more fatigue and negative values indicate less fatigue. |
| Number of Participants With Adverse Events in the Ginseng and Placebo Arms | From baseline to week 4 (28 days of study drugs) | Adverse events (AEs) were assessed from baseline to wk 4 using the NIH Division of AIDS (DAIDS) Grading Toxicity Table, a well known tool used by NIH networks for assessing the severity of AEs in participants enrolled in clinical trials. Reporting the number of participants in each arm who experienced adverse events. |
| Inflammatory Markers | From baseline to week 4 (28 days of study drugs) | Laboratory - Inflammatory Markers (IMs): Change in Interleukin (IL) -6 and soluble receptors of tumor necrosis factor (TNF) α 1 and 2 (sTNFR1 and sTNFR2) from baseline to week 4. Negative values indicate less change in inflammatory markers. |
Countries
United States
Participant flow
Recruitment details
Study participants were recruited from 2/13/13 through 10/19/15 from local HIV specialty clinics.
Pre-assignment details
Participants who met study criteria returned for an enrollment visit for randomization. Study drugs (placebo or ginseng) were dispensed by the Investigational Pharmacy. Participants were instructed to take study drugs daily for 28 days. They returned 2 wks after finishing taking study drugs for a final visit. No wash out or run-in periods.
Participants by arm
| Arm | Count |
|---|---|
| American Ginseng 1000 mg/Day 4-week of American ginseng 1000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks. | 32 |
| Placebo for American Ginseng 1000 mg/Day 4-week of placebo for American ginseng 1000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day | 17 |
| American Ginseng 3000 mg/Day 4-week of American ginseng 3000 mg/day every morning
American ginseng: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks. | 31 |
| Placebo for American Ginseng 3000 mg/Day 4-week of placebo for American ginseng 3000 mg/day every morning
Placebo for American ginseng: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day | 16 |
| Total | 96 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 1 | 0 | 0 | 2 |
Baseline characteristics
| Characteristic | American Ginseng 1000 mg/Day | Placebo for American Ginseng 1000 mg/Day | American Ginseng 3000 mg/Day | Placebo for American Ginseng 3000 mg/Day | Total |
|---|---|---|---|---|---|
| Age, Continuous | 51.8 years STANDARD_DEVIATION 7.5 | 52.1 years STANDARD_DEVIATION 9.5 | 53.7 years STANDARD_DEVIATION 6.8 | 50.2 years STANDARD_DEVIATION 4.83 | 52.2 years STANDARD_DEVIATION 7.3 |
| Region of Enrollment United States | 32 Participants | 17 Participants | 31 Participants | 16 Participants | 96 Participants |
| Sex: Female, Male Female | 14 Participants | 8 Participants | 13 Participants | 9 Participants | 44 Participants |
| Sex: Female, Male Male | 18 Participants | 9 Participants | 18 Participants | 7 Participants | 52 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 32 | 0 / 17 | 0 / 31 | 0 / 16 |
| other Total, other adverse events | 30 / 32 | 16 / 17 | 31 / 31 | 13 / 16 |
| serious Total, serious adverse events | 2 / 32 | 2 / 17 | 4 / 31 | 2 / 16 |
Outcome results
Primary
Change in Fatigue Severity Score (FSS)
Change in FSS score from baseline to Week 4. The change in fatigue as measured by the FSS (Week 4 minus Baseline) using the Wilcoxon test. The FSS is a scale score ranging from 1 to 63 with higher scores indicative of more fatigue. A negative number indicates a decline in the FSS scale. Participants with FSS data at both times points were assessed.
Time frame: From baseline to week 4 (28 days of study drugs)
Population: There was one missing scale from the ginseng 3000 arm
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in Fatigue Severity Score (FSS) | -24.7 units on a scale | Standard Deviation 18.6 |
| Placebo for American Ginseng 1000 mg/Day | Change in Fatigue Severity Score (FSS) | -16.3 units on a scale | Standard Deviation 18.6 |
| American Ginseng 3000 mg/Day | Change in Fatigue Severity Score (FSS) | -16.9 units on a scale | Standard Deviation 15 |
| Placebo for American Ginseng 3000 mg/Day | Change in Fatigue Severity Score (FSS) | -21.6 units on a scale | Standard Deviation 16 |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between armsp-value: 0.73Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.15Wilcoxon (Mann-Whitney)
Secondary
Change in CD4 Cell Count
Laboratory: Change in absolute cluster of differentiation 4 (CD4) cell count from baseline to week 5. Negative values mean decline in CD4 cell count.
Time frame: From baseline to week 5 (28 days of study drugs)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in CD4 Cell Count | 3.45 cells per cubic millimeter | Standard Deviation 111.5 |
| Placebo for American Ginseng 1000 mg/Day | Change in CD4 Cell Count | 56.6 cells per cubic millimeter | Standard Deviation 147.5 |
| American Ginseng 3000 mg/Day | Change in CD4 Cell Count | -23.1 cells per cubic millimeter | Standard Deviation 148.4 |
| Placebo for American Ginseng 3000 mg/Day | Change in CD4 Cell Count | 34.4 cells per cubic millimeter | Standard Deviation 99.8 |
Comparison: Testing whether the changes from baseline to week 5 are significantly different between arms.p-value: 0.31Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.71Wilcoxon (Mann-Whitney)
Secondary
Change in Epworth Sleepiness Scale
Questionnaire: Change in Epworth Sleepiness Scale (ESS) score from baseline to week 4. The ESS is scale ranges from 0 to 24; higher scores mean worse sleep disorder while a negative score indicates less sleep disorder. The ESS was used to supplement the data obtained from the FSS.
Time frame: From baseline to week 4 (28 days of study drugs)
Population: There was one missing questionnaire from the ginseng 3000 arm
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in Epworth Sleepiness Scale | -5.74 units on a scale | Standard Error 7.15 |
| Placebo for American Ginseng 1000 mg/Day | Change in Epworth Sleepiness Scale | -6.35 units on a scale | Standard Error 4.43 |
| American Ginseng 3000 mg/Day | Change in Epworth Sleepiness Scale | -6.97 units on a scale | Standard Error 5.23 |
| Placebo for American Ginseng 3000 mg/Day | Change in Epworth Sleepiness Scale | -5.93 units on a scale | Standard Error 3.17 |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.7454Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.7391Wilcoxon (Mann-Whitney)
Secondary
Change in Insomnia Severity Index
Questionnaire: Change in Insomnia Severity Index (ISI) score from baseline to week 4. The ISI scale ranges from 0 to 28; higher scores mean worse insomnia while negative scores indicate less insomnia. The ISI was used to supplement the data obtained from the FSS.
Time frame: From baseline to week 4 (28 days of study drugs)
Population: There was one missing ISI in the ginseng 3000 mg arm
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in Insomnia Severity Index | -6.9 units on a scale | Standard Deviation 6.07 |
| Placebo for American Ginseng 1000 mg/Day | Change in Insomnia Severity Index | -5.47 units on a scale | Standard Deviation 5.15 |
| American Ginseng 3000 mg/Day | Change in Insomnia Severity Index | -3.43 units on a scale | Standard Deviation 5.49 |
| Placebo for American Ginseng 3000 mg/Day | Change in Insomnia Severity Index | -3.57 units on a scale | Standard Deviation 5.17 |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.17Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.51Wilcoxon (Mann-Whitney)
Secondary
Change in Medical Outcomes Study HIV Health Survey
Questionnaire: Change in Medical Outcomes Study (MOS) HIV Health Survey score from baseline to week 4. We evaluated the MOS Energy Fatigue scores; the MOS scale ranges from 0-100; higher scores mean more energy. The MOS was used to supplement the data obtained from the FSS.
Time frame: From baseline to week 4 (28 days of study drugs)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in Medical Outcomes Study HIV Health Survey | 22.4 units on a scale | Standard Deviation 20.9 |
| Placebo for American Ginseng 1000 mg/Day | Change in Medical Outcomes Study HIV Health Survey | 17.6 units on a scale | Standard Deviation 19.5 |
| American Ginseng 3000 mg/Day | Change in Medical Outcomes Study HIV Health Survey | 24.0 units on a scale | Standard Deviation 22 |
| Placebo for American Ginseng 3000 mg/Day | Change in Medical Outcomes Study HIV Health Survey | 23.1 units on a scale | Standard Deviation 21.3 |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.7884Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.5532Wilcoxon (Mann-Whitney)
Secondary
Change in Patient Health Questionnaire 9
Questionnaire: Change in Patient Health Questionnaire 9 (PHQ9) score from baseline to week 4. The scale for the PHQ9 score ranges from 0 to 27; higher scores mean worse depression; negative scores indicate less depression. We compared PHQ 9 scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. The PHQ9 was used to supplement the data obtained from the FSS.
Time frame: From baseline to week 4 (28 days of study drugs)
Population: There was one missed PHQ9 in the ginseng 3000 mg arm
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in Patient Health Questionnaire 9 | -5.52 units on a scale | Standard Deviation 4.76 |
| Placebo for American Ginseng 1000 mg/Day | Change in Patient Health Questionnaire 9 | -5.59 units on a scale | Standard Deviation 4.84 |
| American Ginseng 3000 mg/Day | Change in Patient Health Questionnaire 9 | -2.87 units on a scale | Standard Deviation 4.2 |
| Placebo for American Ginseng 3000 mg/Day | Change in Patient Health Questionnaire 9 | -3.86 units on a scale | Standard Deviation 3.16 |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.6818Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.0579Wilcoxon (Mann-Whitney)
Secondary
Change in Plasma HIV RNA
Laboratory: Change in plasma HIV RNA from baseline to week 4. A negative value means a drop in plasma HIV RNA.
Time frame: From baseline to week 4 (28 days of study drugs)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in Plasma HIV RNA | 1.94 copies/mL | Standard Deviation 6.19 |
| Placebo for American Ginseng 1000 mg/Day | Change in Plasma HIV RNA | -0.06 copies/mL | Standard Deviation 4.78 |
| American Ginseng 3000 mg/Day | Change in Plasma HIV RNA | 1.32 copies/mL | Standard Deviation 7.02 |
| Placebo for American Ginseng 3000 mg/Day | Change in Plasma HIV RNA | 0.0 copies/mL | Standard Deviation 0 |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.18Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.19Wilcoxon (Mann-Whitney)
Secondary
Change in PROMIS Fatigue
Questionnaire: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue score from baseline to week 4. Change in PROMIS fatigue score from baseline to Week 4. The change in fatigue as measured by the PROMIS fatigue (Week 4 minus Baseline) using the Wilcoxon test. The PROMIS fatigue is a scale with normalized mean of 50 and standard deviation (SD) of 10. Higher mean values mean more fatigue and negative values indicate less fatigue.
Time frame: From baseline to week 4 (28 days of study drugs).
Population: There was one missed PROMIS fatigue questionnaire in the ginseng 3000 mg arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in PROMIS Fatigue | -12.5 units on a scale | Standard Deviation 11.8 |
| Placebo for American Ginseng 1000 mg/Day | Change in PROMIS Fatigue | -11.1 units on a scale | Standard Deviation 11 |
| American Ginseng 3000 mg/Day | Change in PROMIS Fatigue | -11.4 units on a scale | Standard Deviation 10.9 |
| Placebo for American Ginseng 3000 mg/Day | Change in PROMIS Fatigue | -9.49 units on a scale | Standard Deviation 11.2 |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.47Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.41Wilcoxon (Mann-Whitney)
Secondary
Change in the Brief Fatigue Inventory
Questionnaire: Change in the Brief Fatigue Inventory (BFI) from baseline to week 4. We compared BFI scores from baseline to week 4 in the ginseng 1000 and 3000 mg arms with the combined placebo arms. We used the BFI Question that assess Worst Fatigue score: 0 to 90 scale. Higher scores means more fatigue; negative values mean less fatigue.The BFI was used to supplement the data obtained from the FSS.
Time frame: Change in BFI scores from baseline to week 4 (28 days of study drugs)
Population: There was on missing questionnaire from the ginseng 3000 arm
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| American Ginseng 1000 mg/Day | Change in the Brief Fatigue Inventory | -44.2 units on a scale | Standard Deviation 34.3 |
| Placebo for American Ginseng 1000 mg/Day | Change in the Brief Fatigue Inventory | -26.5 units on a scale | Standard Deviation 28.5 |
| American Ginseng 3000 mg/Day | Change in the Brief Fatigue Inventory | -42.7 units on a scale | Standard Deviation 32.4 |
| Placebo for American Ginseng 3000 mg/Day | Change in the Brief Fatigue Inventory | -37.9 units on a scale | Standard Deviation 35.1 |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.1329Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.1191Wilcoxon (Mann-Whitney)
Secondary
Changes in Clinical Global Impressions
Questionnaire: Change in Clinical Global Impressions (CGI) scores from baseline to week 4. CGI is an instrument for making global assessments of worsening or improvement during interventional trials. The subject rates the change in the overall status since beginning the intervention (ranging from: very much improved, much improved, minimally improved, no change, and minimally worse). We assessed the number of participants who rated very much improved.
Time frame: From baseline to week 4 (28 days of study drugs)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| American Ginseng 1000 mg/Day | Changes in Clinical Global Impressions | 3 Participants |
| Placebo for American Ginseng 1000 mg/Day | Changes in Clinical Global Impressions | 3 Participants |
| American Ginseng 3000 mg/Day | Changes in Clinical Global Impressions | 7 Participants |
| Placebo for American Ginseng 3000 mg/Day | Changes in Clinical Global Impressions | 0 Participants |
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.9885Wilcoxon (Mann-Whitney)
Comparison: Testing whether the changes from baseline to week 4 are significantly different between arms.p-value: 0.2898Wilcoxon (Mann-Whitney)
Secondary
Inflammatory Markers
Laboratory - Inflammatory Markers (IMs): Change in Interleukin (IL) -6 and soluble receptors of tumor necrosis factor (TNF) α 1 and 2 (sTNFR1 and sTNFR2) from baseline to week 4. Negative values indicate less change in inflammatory markers.
Time frame: From baseline to week 4 (28 days of study drugs)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| American Ginseng 1000 mg/Day | Inflammatory Markers | sTNFR1 | 19.5 pg/ml | Standard Deviation 135.5 |
| American Ginseng 1000 mg/Day | Inflammatory Markers | IL-6 | 0.22 pg/ml | Standard Deviation 1.18 |
| American Ginseng 1000 mg/Day | Inflammatory Markers | sTNFR2 | 183.5 pg/ml | Standard Deviation 667.9 |
| Placebo for American Ginseng 1000 mg/Day | Inflammatory Markers | IL-6 | 0.53 pg/ml | Standard Deviation 1.99 |
| Placebo for American Ginseng 1000 mg/Day | Inflammatory Markers | sTNFR1 | -15.5 pg/ml | Standard Deviation 154.5 |
| Placebo for American Ginseng 1000 mg/Day | Inflammatory Markers | sTNFR2 | 4.08 pg/ml | Standard Deviation 580.5 |
| American Ginseng 3000 mg/Day | Inflammatory Markers | IL-6 | 0.079 pg/ml | Standard Deviation 1.63 |
| American Ginseng 3000 mg/Day | Inflammatory Markers | sTNFR2 | -207.7 pg/ml | Standard Deviation 1156.1 |
| American Ginseng 3000 mg/Day | Inflammatory Markers | sTNFR1 | 15.2 pg/ml | Standard Deviation 170.5 |
| Placebo for American Ginseng 3000 mg/Day | Inflammatory Markers | sTNFR1 | -6.24 pg/ml | Standard Deviation 142 |
| Placebo for American Ginseng 3000 mg/Day | Inflammatory Markers | IL-6 | 0.33 pg/ml | Standard Deviation 1.33 |
| Placebo for American Ginseng 3000 mg/Day | Inflammatory Markers | sTNFR2 | -201.7 pg/ml | Standard Deviation 1156.1 |
Comparison: Testing whether the IL-6 level changes from baseline to week 4 are significantly different between arms.p-value: 0.6Wilcoxon (Mann-Whitney)
Comparison: Testing whether the IL-6 level changes from baseline to week 4 are significantly different between arms.p-value: 0.28Wilcoxon (Mann-Whitney)
Comparison: Testing whether the sTNFR1 level changes from baseline to week 4 are significantly different between arms.p-value: 0.41Wilcoxon (Mann-Whitney)
Comparison: Testing whether the sTNFR1 level changes from baseline to week 4 are significantly different between arms.p-value: 0.72Wilcoxon (Mann-Whitney)
Comparison: Testing whether the sTNFR2 level changes from baseline to week 4 are significantly different between arms.p-value: 0.34Wilcoxon (Mann-Whitney)
Comparison: Testing whether the sTNFR2 level changes from baseline to week 4 are significantly different between arms.p-value: 0.58Wilcoxon (Mann-Whitney)
Secondary
Number of Participants With Adverse Events in the Ginseng and Placebo Arms
Adverse events (AEs) were assessed from baseline to wk 4 using the NIH Division of AIDS (DAIDS) Grading Toxicity Table, a well known tool used by NIH networks for assessing the severity of AEs in participants enrolled in clinical trials. Reporting the number of participants in each arm who experienced adverse events.
Time frame: From baseline to week 4 (28 days of study drugs)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| American Ginseng 1000 mg/Day | Number of Participants With Adverse Events in the Ginseng and Placebo Arms | 30 Participants |
| Placebo for American Ginseng 1000 mg/Day | Number of Participants With Adverse Events in the Ginseng and Placebo Arms | 16 Participants |
| American Ginseng 3000 mg/Day | Number of Participants With Adverse Events in the Ginseng and Placebo Arms | 31 Participants |
| Placebo for American Ginseng 3000 mg/Day | Number of Participants With Adverse Events in the Ginseng and Placebo Arms | 13 Participants |